SMASH

Project "SMASH" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

Monitoring of blood glucose concentration in diabetics is mandatory for managing the pathology evolution, but it is still performed through invasive devices (mainly blood-prick tests) which cause pain and are unable to provide continuous, realtime monitoring. The same shortages can be found in the monitoring of other key biomarkers, such as lactate level, which is a key factor for customizing the training of professional athletes and prevent muscle injuries, and is currently measured through prick test or ex-post through lab exams. Innovosens is a high-tech start-up company specialized in bio-chemical analysis and micro-sensing devices which developed SMASH, the first non-invasive, multiparametric wearable sensor for continuous monitoring of glucose and lactate levels. Through an innovative patented microfluidic system, the sensor is able to collect sweat from the skin, analyse both the biomarkers level, and continuously replenish the reservoir with fresh sweat for updated data. Diabetics patients will be able to measure their glucose level non-invasively, continuously and in real-time, through data wirelessly transmitted from the device to a mobile app, thus promptly reacting to acute levels with corrective dietary or drug intake. At the same time, the real-time monitoring of lactate level will provide athletes and their coaches with the unprecedented possibility to prevent lacto-acidosis, thus customising and maximising training sessions and preventing the risk of injuries. The Phase 1 project will be key for defining the final device design by interacting with end-users and key stakeholders, and for consolidating the business model by devising the most appropriate pricing and commercialization strategy, with a view to the market launch in 2021.